BC Innovations | Jul 26, 2018
Emerging Company Profile

The universe in an exosome

Versatope Therapeutics Inc. is using exosomes from commensal E. coli as the backbone of a universal influenza vaccine that should be cheaper and easier to manufacture than other vesicle-based vaccines. The company’s technology was developed...
BC Week In Review | Oct 31, 2011
Clinical News

Influenza vaccines infectious data

Researchers at the university and colleagues reported data from a meta-analysis of 17 randomized controlled trials and 14 observational studies of approved influenza vaccines suggesting that the vaccines can provide moderate protection against virologically-confirmed influenza....
BC Week In Review | Jan 3, 2011
Company News

Novartis sales and marketing update

Novartis recalled one lot of Fluvirin influenza vaccine multi-dose vials. The company recalled lot #111812P1 of the trivalent seasonal influenza vaccine after cracked and broken vials were discovered. Fluvirin is approved in more than 20...
BC Week In Review | May 10, 2010
Clinical News

Dynavax preclinical data

In mice, M2e/NP-ISS plus Fluvirin provided 6.9- and 3.4-fold increases in virus neutralization titers against the A/Brisbane/59/2007 H1N1 virus subtype after the 1st and 2nd injection, respectively, compared with Fluvirin alone. A single dose of...
BioCentury | Jan 11, 2010
Finance

New Products to Watch

New Products to Watch Selected drugs that received regulatory approval in 2009. Company Product Indication 2009 approval Allergan Inc. (NYSE:AGN) Ozurdex dexamethasone Macular edema U.S. Allos Therapeutics Inc. (NASDAQ:ALTH) Folotyn pralatrexate Relapsed or refractory peripheral...
BC Week In Review | Jan 4, 2010
Clinical News

Celtura regulatory update

Novartis said its influenza A (H1N1) 2009 monovalent vaccines Celtura, Focetria and Fluvirin received prequalification from the World Health Organization (WHO) for use in national immunization programs, which makes vaccines available for purchase through United...
BC Week In Review | Sep 21, 2009
Clinical News

Fluvirin regulatory update

FDA said it approved 4 vaccines against swine influenza A (H1N1). The agency said the vaccines from sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France), CSL Ltd. (ASX:CSL, Melbourne, Australia), MedImmune LLC and Novartis will be distributed...
BC Week In Review | Aug 24, 2009
Clinical News

NanoBio preclinical data

In ferrets, W805EC vaccine adjuvant significantly enhanced the immune response to marketed influenza vaccines Fluvirin from Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) and Fluzone from sanofi-aventis Group (Euronext:SAN; NYSE:SNY, Paris, France). Specifically, the intranasal vaccines...
BC Week In Review | Jul 27, 2009
Clinical News

Afluria regulatory update

CSL Ltd. (ASX:CSL), Melbourne, Australia   Product: Afluria   Business: Infectious   FDA approved 6 vaccines to prevent 2009-10 seasonal influenza. The vaccines contain an A/Brisbane/59/2007 (H1N1)-like virus, an A/Brisbane/10/2007 (H3N2)-like virus, and a B/Brisbane/60/2008-like...
BC Week In Review | Jul 27, 2009
Clinical News

FluMist regulatory update

AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K.   CSL Ltd. (ASX:CSL), Melbourne, Australia   GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), London, U.K.   Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland   sanofi-aventis Group (Euronext:SAN; NYSE:SNY), Paris, France   Product:...
Items per page:
1 - 10 of 108